Welcome to Flow Pharma Inc.

Page Loading...

Menu

FLOVID-20

Under Development, FDA Approval Required

A Targeted T-cell Immunotherapy for COVID-19 positive patients administered by your doctor using a standard inhalation nebulizer. FLOVID-20 is being developed for patients recently exposed to SARS-CoV-2 who are at risk of developing the COVID-19 disease.

by Flow Pharma, Inc., a California BioPharma Corporation
Ebola Vaccine Creator
United States Department of Defense Contractor
COVID-19 Public-Private Partnership Participant


Learn More

Treatment For All COVID Virus Variants

Our FLOVID-20 targeted T-Cell immunotherapy is designed to work against all of the potential variants of the COVID-19 Virus

 

Virus Samples Analyzed: 380,587

Viral sequence data courtesy of GISAID Database


* Spike protein samples (red) are plotted as a mutant if 6 to 12 amino acid substitutions are detected. Any nucleocapsid protein amino acid substitution in the FLOVID-20 subset (blue), is plotted as mutant.


Learn More

Forget the Needle

And forget the refrigerator. One and done.

An inexpensive powder, stable at room temperature.


Learn More

Seeing is Believing

FLOVID-20 showed efficacy in a pre-clinical study in non-human primates, protecting against COVID-19 pneumonia.


Learn More

Available and Scalable

Currently produced and rapidly scalable.

An innovative, inexpensive, COVID-19 treatment.


Learn More
blob-1
blob-2
Our Mission

Flow Pharma engineers and manufactures state-of-the-art biomedicines.

Our unique patented delivery systems and biotechnology are ideally suited for curative intervention in COVID-19, Ebola, and treatment-resistant cancers.


Our Biomedicines


FLOVID-20

COVID-19

A prophylactic needle-free nebulizer treatment to prevent COVID-19 in both virus-exposed and healthy patient populations. A unique targeted T-Cell immunotherapy biomedicine designed to help cure and prevent COVID-19.

FlowVax Ebola

Ebola

By relying on T-cells rather than antibodies, FlowVax Ebola provides long lasting protection through enhanced immune targeting and surveillance of the hidden Ebola virus nucleocapsid protein. FLOVID-20 targets the SARS-CoV-2 virus in the same way.

FlowVax Marburg

Marburg

Marburg is an Ebola-like virus weaponized by hostile forces. Working directly with the United States Dept. of Defense, we are developing FlowVax Marburg, a prophylactic nebulized biomedicine to protect at-risk military forces and civilians.

FlowVax BreastCA

Cancer

A revolutionary approach to breast cancer that utilizes T-cell biomedicines to provide highly efficacious therapy.

Our Medicine

All COVID-19 patients​
deserve meaningful treatment.

Efficacy, Safety, and Convenience are everything. We believe FLOVID-20 can provide it.

Under Development, FDA Approval Required

  • benefit-icon-0

    Efficacy

    designed to reduce hospitalizations and deaths

  • benefit-icon-1

    Safety

    using components currently used in FDA approved medications with no observed adverse events in our pre-clinical studies

  • benefit-icon-2

    Convenience

    inhaled, office-administered, inexpensive, hospital-free​